<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SERTRALINE HYDROCHLORIDE</span><br/>(ser'tra-leen)<br/><span class="topboxtradename">Zoloft<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antidepressant</span>; <span class="classification">selective serotonin reuptake inhibitor (ssri)</span><br/><b>Prototype: </b>Fluoxetine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg tablets; 20 mg/mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Potent inhibitor of serotonin (5HT) reuptake in the brain, and chemically unrelated to TCA, tetracyclic or other available
         antidepressants. Chronic administration of sertraline results in down regulation of norepinephrine, a reaction found with
         other effective antidepressants. Sertraline does not inhibit MAO.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Treats depression, obsessive-compulsive disorder, anxiety, and panic disorder.</p>
<h1><a name="uses">Uses</a></h1>
<p>Major depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, premenstrual dysphoric disorder,
         generalized anxiety, post-traumatic stress disorder.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Eating disorders, generalized anxiety disorder.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients taking <small>MAO</small> inhibitors or within 14 d of discontinuing <small>MAO</small> inhibitor; antabuse; suicidal ideation, hyponatremia; mania or hypomania, pregnancy (category C); third trimester of pregnancy.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Seizure disorders, major affective disorders, suicidal patients; liver dysfunction, renal impairment; abrupt discontinuation;
         anorexia nervosa, recent history of MI or unstable cardiac disease, dehydration; diabetes mellitus; older adults; ECT therapy,
         seizure disorder, seizures. Unknown if sertraline is excreted in breast milk. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression, Anxiety</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Begin with 50 mg/d, gradually increase every few weeks according to response (range: 50200 mg)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 25 mg/d<br/><br/><span class="indicationtitle">Premenstrual Dysphoric Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Begin with 50 mg/d for first cycle, may titrate up to 150 mg/d<br/><br/><span class="indicationtitle">Obsessive-Compulsive Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Begin with 50 mg/d, may titrate at weekly intervals up to 200 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>612 y</i>, Begin with 25 mg/d, may increase by 50 mg/wk, as tolerated and needed, up to 200 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give in the morning or evening.</li>
<li>Do not give concurrently with a <small>MAO</small> inhibitor or within 14 d of discontinuing an <small>MAOI</small>.
         </li>
<li>Dilute concentrate before use with 4 oz of water, ginger ale, lemon/lime soda, lemonade, or orange juice ONLY. Give immediately
            after mixing. Caution with latex sensitivity, as the dropper contains dry natural rubber.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Palpitations, chest pain, hypertension, hypotension, edema, syncope, tachycardia. <span class="typehead">CNS:</span>
<span class="speceff-common">Agitation, insomnia, headache, dizziness, somnolence, fatigue,</span> ataxia, incoordination, vertigo, abnormal dreams, aggressive behavior, delusions, hallucinations, emotional lability, paranoia,
      suicidal ideation, depersonalization. <span class="typehead">Endocrine:</span> Gynecomastia, male sexual dysfunction. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, constipation, indigestion, anorexia, flatulence, abdominal pain, dry mouth. <span class="typehead">Special Senses:</span> Exophthalmos, blurred vision, dry eyes, diplopia, photophobia, tearing, conjunctivitis, mydriasis. <span class="typehead">Skin:</span> Rash, urticaria, acne, alopecia. <span class="typehead">Respiratory:</span> Rhinitis, pharyngitis, cough, dyspnea, bronchospasm. <span class="typehead">Body as a Whole:</span> Myalgia, arthralgia, muscle weakness. <span class="typehead">Metabolic:</span> Hyponatremia in older adults. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause asymptomatic elevations in <span class="alt">liver function tests.</span> Slight decrease in <span class="alt">uric acid.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">maoi</span>s (e.g., <b>selegiline,</b>
<b>phenelzine</b>) should be stopped 14 d before sertraline is started because of serious problems with other <span class="classification">serotonin reuptake inhibitors</span> (shivering, nausea, diplopia, confusion, anxiety). <b>Sertraline may increase levels and toxicity of diazepam, pimozide, tolbutamide.</b> Use cautiously with other centrally acting CNS drugs; increase risk of <b>ergotamine</b> toxicity with <b>dihydroergotamine, ergotamine.</b> Concentrate interacts with <b>disulfiram.</b> <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may cause <b>serotonin</b> syndrome (headache, dizziness, sweating, agitation). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from GI tract. <span class="typehead">Onset:</span> 24 wk.  <span class="typehead">Distribution:</span> 99% protein bound; not known if distributed into breast milk. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism in liver to inactive metabolites. <span class="typehead">Elimination:</span> 4045% excreted in urine, 4045% in feces. <span class="typehead">Half-Life:</span> 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Supervise patients at risk for suicide closely during initial therapy.</li>
<li>Monitor for worsening of depression or emergence of suicidal ideation.</li>
<li>Monitor older adults for fluid and sodium imbalances.</li>
<li>Monitor patients with a history of a seizure disorder closely.</li>
<li>Lab tests: Monitor PT and INR with patients receiving concurrent warfarin therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report diarrhea, nausea, dyspepsia, insomnia, drowsiness, dizziness, or persistent headache to physician.</li>
<li>Report signs of bleeding promptly to physician when taking concomitant warfarin.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>